Skip to main navigation
 
Zentalis

Top Navigation

  • About Us
    • Our Company
      • Management Team
      • Board of Directors
      • Scientific Advisory Board
      • Business Advisory Board
      • Partners & Collaborations
    • Contact Us
  • Our Pipeline
    • Pipeline
      • ZN-c3
      • ZN-c5
      • ZN-d5
      • ZN-e4
    • Clinical Trials
  • Our Approach
    • Integrated Discovery Engine
    • Supporting Publications
  • Investors & Media
    • Investor Home
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Financials & Filings
      • SEC Filings
    • Corporate Governance
      • Documents & Charters
      • Management Team
      • Board of Directors
      • Scientific Advisory Committee
      • Business Advisory Committee
      • Committee Composition
    • Investor Resources
      • Investor FAQs
      • Investor Contact
      • Email Alerts
  • Careers

Investors/Media

Press Releases

Press Releases

Mar 29, 2022
Zentalis Pharmaceuticals and Caris Life Sciences Announce Strategic Collaboration to Support Clinical Studies, Initially Focused on the Wee1 Inhibitor ZN-c3
Mar 22, 2022
Zentalis Pharmaceuticals Announces First Patient Dosed in the Potentially Registrational Phase 1/2 Study of BCL-2 inhibitor ZN-d5 in Patients with Relapsed or Refractory Light Chain (AL) Amyloidosis
Mar 15, 2022
Stand Up to Cancer Announces $1 Million Donation From Zentalis Pharmaceuticals To Fund Targeted Cancer Therapy Research
Mar 09, 2022
Zentalis Pharmaceuticals to Present at the Oppenheimer Annual Healthcare Conference
Mar 08, 2022
Zentalis Pharmaceuticals to Present New Clinical and Preclinical Data at the AACR Annual Meeting 2022
Feb 24, 2022
Zentalis Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Operational Update
Feb 03, 2022
Zentalis Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Pagination

  • First page « first
  • Previous page ‹ previous
  • Page 1
  • Current page 2
Displaying 11 - 17 of 17

Investors/Media

  • Investor Home
  • News & Events
    • Press Releases
    • Events & Presentations
  • Stock Information
    • Stock Quote & Chart
    • Historic Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Financials & Filings
    • SEC Filings
  • Corporate Governance
    • Documents & Charters
    • Management Team
    • Board of Directors
    • Scientific Advisory Committee
    • Business Advisory Committee
    • Committee Composition
  • Investor Resources
    • Investor FAQs
    • Investor Contact
    • Email Alerts

Investor Contact

Alexandra Roy
Solebury Trout
aroy@soleburytrout.com

Media Contact

Julia Deutsch
Solebury Trout
jdeutsch@soleburytrout.com

“The sun is but a morning star.”

Zentalis Logo

Corporate Office

530 Seventh Avenue
Suite 2201
New York, NY 10018

Science Center

10835 Road to the Cure
Suite 205
San Diego, CA 92121

For More Information

1-212-433-3791
info@zentalis.com

Footer

  • Privacy Policy
  • Terms of Use
  • Expanded Access Policy
  • Site Map

Copyright © 2022 Zentalis Pharmaceuticals. All Rights Reserved.